Emerald Advisers LLC Invests $20.13 Million in Palvella Therapeutics, Inc. $PVLA

Emerald Advisers LLC acquired a new position in Palvella Therapeutics, Inc. (NASDAQ:PVLA) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 161,500 shares of the company’s stock, valued at approximately $20,131,000.

Several other large investors also recently added to or reduced their stakes in the business. First Light Asset Management LLC bought a new position in Palvella Therapeutics in the 3rd quarter worth about $33,949,000. Jennison Associates LLC raised its holdings in shares of Palvella Therapeutics by 262.4% in the 4th quarter. Jennison Associates LLC now owns 387,483 shares of the company’s stock valued at $40,558,000 after acquiring an additional 280,573 shares in the last quarter. Fred Alger Management LLC boosted its position in shares of Palvella Therapeutics by 1,279.1% during the 3rd quarter. Fred Alger Management LLC now owns 186,751 shares of the company’s stock valued at $11,707,000 after acquiring an additional 173,209 shares during the last quarter. Profund Advisors LLC bought a new stake in shares of Palvella Therapeutics during the 4th quarter valued at about $608,000. Finally, Vanguard Group Inc. grew its holdings in shares of Palvella Therapeutics by 13.3% during the fourth quarter. Vanguard Group Inc. now owns 560,616 shares of the company’s stock worth $58,680,000 after purchasing an additional 65,960 shares in the last quarter. Institutional investors own 40.11% of the company’s stock.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total transaction of $476,360.46. Following the transaction, the chief operating officer directly owned 2,154 shares in the company, valued at $238,512.42. This trade represents a 66.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on PVLA. Wall Street Zen cut shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. HC Wainwright boosted their price target on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Chardan Capital reissued a “buy” rating and issued a $240.00 price target on shares of Palvella Therapeutics in a report on Thursday, May 21st. Finally, Stephens restated an “overweight” rating and set a $220.00 price objective on shares of Palvella Therapeutics in a research report on Thursday, May 21st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Palvella Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $199.53.

Palvella Therapeutics Trading Up 0.9%

PVLA opened at $146.03 on Tuesday. The stock has a 50-day moving average price of $123.01 and a 200-day moving average price of $114.06. Palvella Therapeutics, Inc. has a 12-month low of $25.80 and a 12-month high of $161.38. The stock has a market capitalization of $2.09 billion, a P/E ratio of -35.02 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, equities research analysts predict that Palvella Therapeutics, Inc. will post -5.26 EPS for the current year.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.